Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cultured Thymus Tissue for Poor Thymic Function
NCT02274662Phase 4Completed
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2014
- Primary completion
- Aug 2023
- Modality
- Cell Therapies
01
Overview
Phase 4, open-label, single-arm trial of Rethymic in congenital athymia, immunodeficiency and autoimmune disease, sponsored by Sumitomo Pharma. Primary endpoints: Survival Rate at End of 1 Year and Survival Rate at End of 2 Year. Started Aug 2014; status: completed.
02
Drugs
Rethymic
03
Conditions
congenital athymiaimmunodeficiencyautoimmune disease
Beyond the preview
Go deeper on NCT02274662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02274662.